What Is Matrixyl?
Matrixyl is the trade name for palmitoyl pentapeptide-4 (pal-KTTKS), a synthetic topical cosmetic lipopeptide — the collagen-fragment sequence KTTKS joined to palmitic acid — marketed as a collagen-boosting anti-ageing skincare ingredient. It is a leave-on cosmetic, not an oral supplement or drug. KTTKS is a “matrikine” fragment derived from type I procollagen, and the proposed mechanism is that it signals dermal fibroblasts to increase synthesis of collagen and other matrix components; the palmitoyl tail is added to help the peptide cross the skin barrier. The efficacy evidence is more developed than for some cosmetic peptides but is still modest in size and partly linked to the ingredient’s developers.
Evidence
The best human evidence is a 12-week, double-blind, placebo-controlled, split-face study of a moisturiser containing pal-KTTKS versus the same moisturiser without it in women with photoaged facial skin; the peptide product produced a statistically significant improvement in fine lines/wrinkles versus the vehicle control by image analysis and was well tolerated 1Reference 1RCTTopical palmitoyl pentapeptide provides improvement in photoaged human facial skin — placebo-controlled split-face studyView study →. That is a genuine, peer-reviewed, vehicle-controlled result, which puts Matrixyl on somewhat firmer footing than purely mechanistic peptides — but it is a single cosmetic study associated with the ingredient’s commercial context, the effect sizes are cosmetic-modest rather than dramatic, and it should not be read as drug-level proof. The underlying “fibroblasts make more collagen” mechanism is supported by laboratory work on the KTTKS sequence, but that is mechanistic support, not a clinical outcome, and I did not attach a specific in-vitro citation in this quick pass. Marketing claims equating it to retinoids or injectables go beyond what this evidence shows.
Dosage & Safety
Matrixyl is a topical cosmetic ingredient, not a dietary supplement or drug, so there is no oral dose; the controlled study used the peptide at a very low concentration (single-digit parts per million of pal-KTTKS in a moisturiser) 1Reference 1RCTTopical palmitoyl pentapeptide provides improvement in photoaged human facial skin — placebo-controlled split-face studyView study →, and product concentrations vary — this is formulation practice, not a personal recommendation. In the studies reviewed it was well tolerated on skin, but formal interaction data, systemic safety and use in pregnancy are not assessed in this pass. Toxicity has not been characterised here beyond that cosmetic-tolerability picture.
References
- Robinson, L. R., et al. (2005). Topical palmitoyl pentapeptide provides improvement in photoaged human facial skin — placebo-controlled split-face study. International Journal of Cosmetic Science. https://doi.org/10.1111/j.1467-2494.2005.00261.x